en · de · es · pt
handling-notes.peptides9000.com › Guide › Receptor Mechanism And Pharmacokinetics — Beginner to Advanced

Receptor Mechanism And Pharmacokinetics — Beginner to Advanced

By Editorial Desk · published 2025-09-10 · last reviewed 2025-10-24 · Guide

PT-141 code is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-10-24. Where a claim depends on a specific study, the study is described rather than over-claimed.

Receptor Mechanism And Pharmacokinetics

The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.

After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.

Receptor Mechanism and Trial Evidence

Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.

Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.

Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.

Pt-141 at a glance

PropertyValueNotes
Primary targetMC4RHighest reported functional activity
Peak plasma timeAbout 1 hourSubcutaneous administration
Elimination half-lifeA few hoursActive fragment may extend effect
Main clearance routeProteolytic degradationNot cytochrome-dependent
Typical assayLC-MS/MSPlasma quantification

Chemical Identity of Bremelanotide

Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.

PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.

The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.

Related pages on this site

Bremelanotide Identity and Background

Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.

Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.

Melanocortin Receptor Agonist Pharmacology

Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.

Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.

Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.

Analytical Methods and Storage Practice

The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.

Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.

Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.

Notes from published material

== Genes == Fibrinogen is made and secreted into the blood primarily by liver hepatocyte cells. Endothelium cells are also reported to make small amounts of fibrinogen, but this fibrinogen has not been fully characterized; blood platelets and their precursors, bone marrow megakaryocytes, while once thought to make fibrinogen, are now known to take up and store but not make the glycoprotein. The final secreted, hepatocyte-derived glycoprotein is composed of two trimers, with each trimer composed of three different polypeptide chains, the fibrinogen alpha chain (also termed the Aα or α chain) encoded by the FGA gene, the fibrinogen beta chain (also termed the Bβ or β chain) encoded by the FGB gene, and the fibrinogen gamma chain (also termed the γ chain) encoded by the FGG gene. All three genes are located on the long or "q" arm of human chromosome 4 (at positions 4q31.3, 4q31.3, and 4q32.1, respectively).

== Purpose == The primary objectives of PMKSY are to attract investments in irrigation system at field level, develop and expand cultivable land in the country, enhance ranch water use in order to minimize wastage of water, enhance crop per drop by implementing water-saving technologies and precision irrigation. The plan additionally calls for bringing ministries, offices, organizations, research and financial institutions occupied with creation and recycling of water under one platform so that an exhaustive and holistic outlook of the whole water cycle is considered. The goal is to open the doors for optimal water budgeting in all sectors. Tagline for PMKSY is "more crop per drop". The Integrated Watershed Management programme was subsumed into the current PMKSY on 26 October 2015. The core implementation activities of IWMP were unchanged and were as per the Common Guidelines 2008 (Revised 2011) of IWMP. Convergence with other Central and State Government schemes, remains the top of the agenda for the programme towards optimal and judicious utilization of financial resources. Action has also been taken to undertake Natural Resources Management activities by utilizing labour component of MGNREGS and to undertake some of the Entry Point Activities in convergence with Swachh Bharat Mission (Gramin).

Hierarchies based on 'naturally' forming family, social and cultural traditions; 'Tight-knit' focus of activity/labor; Fraternal or nepotistic value systems; Personalized activity; including family rivalries, territorial disputes, recruitment and training of family members, etc.; Entrenched belief systems, reliance of tradition (including religion, family values, cultural expectations, class politics, gender roles, etc.); and, Communication and rule enforcement mechanisms dependent on organizational structure, social etiquette, history of criminal involvement, and collective decision-making.

=== Primary source === Cyclooxygenase-1 and cyclooxygenase-2 metabolize arachidonic acid to the 15-hydroperoxy, 20 carbon prostaglandin (PG) intermediate, PGG2, and then to the 15-hydroxy, 20 carbon intermediate, prostaglandin H2 (PGH2). Thromboxane synthase further metabolizes PGH2 to the 20 carbon product, thromboxane A2, the 17 carbon product, 12-HHT, and the 3 carbon product, malonyldialdehyde. Platelets express cyclooxygenase and thromboxane synthase enzymes, producing PGG2, PGH2, and TXA2 in response to platelet aggregating agents such as thrombin; these metabolites act as autocrines by feeding back to promote further aggregation of their cells of origin and as paracrines by recruiting nearby platelets into the response as well as exerting effects on other nearby tissues such as contracting blood vessels. These effects combine to trigger blood clotting and limiting blood loss. 12-HHT is a particularly abundant product of these pro-clotting responses, accounting for about one third of the total amount of arachidonic acid metabolites formed by physiologically stimulated human platelets. Its abundant production during blood clotting, the presence of cyclooxygenases and to a lesser extent thromboxane synthase in a wide range of cell types and tissue, and its production by other pathways imply that 12-HHT has one or more important bioactivities relevant to clotting and, perhaps, other responses.

Sources: en.wikipedia.org

Background from the literature

=== In the field === The study of birds in the field was helped enormously by improvements in optics. Photography made it possible to document birds in the field with great accuracy. High-power spotting scopes today allow observers to detect minute morphological differences that were earlier possible only by examination of the specimen "in the hand".

Schwann cells respond to loss of axons by extrusion of their myelin sheaths, downregulation of myelin genes, dedifferentiation and proliferation. They finally align in tubes (Büngner bands) and express surface molecules that guide regenerating fibers. Within 4 days of the injury, the distal end of the portion of the nerve fiber proximal to the lesion sends out sprouts towards those tubes and these sprouts are attracted by growth factors produced by Schwann cells in the tubes. If a sprout reaches the tube, it grows into it and advances about 1 mm per day, eventually reaching and reinnervating the target tissue. If the sprouts cannot reach the tube, for instance because the gap is too wide or scar tissue has formed, surgery can help to guide the sprouts into the tubes. Regeneration is efficient in the PNS, with near complete recovery in case of lesions that occur close to the distal nerve terminal. However recovery is hardly observed at all in the spinal cord. One crucial difference is that in the CNS, including the spinal cord, myelin sheaths are produced by oligodendrocytes and not by Schwann cells.

=== Purpose in life === Purpose in life refers broadly to the pursuit of life satisfaction. It has also been found that those with high purpose in life scores have strong goals and sense of direction. They feel there is meaning to their past and present life, and hold beliefs that continue to give their life purpose. Research in the past has focused on purpose in the face of adversity (what is awful, difficult, or absurd in life). Recently, research has shifted to include a focus on the role of purpose in personal fulfillment and self-actualization. The self-control approach, as expounded by C. R. Snyder, focusses on exercising self-control to achieve self-esteem by fulfilling goals and feeling in control of our own success. This is further reinforced by a sense of intentionality in both efforts and outcomes. The intrinsic motivation approach of Viktor Frankl emphasized finding value in three main areas: creative, experiential, and attitudinal. Creative values are expressed in acts of creating or producing something. Experiential values are actualized through the senses, and may overlap the hedonistic view of happiness. Attitudinal values are prominent for individuals who are unable to pursue the preceding two classes of values. Attitudinal values are believed to be primarily responsible for allowing individuals to endure suffering with dignity.

== Selected publications == Zubarev, R. A.; Kelleher, N. L.; McLafferty, F. W. (1998). "Electron Capture Dissociation of Multiply Charged Protein Cations. A Non-ergodic Process". Journal of the American Chemical Society. 120 (13): 3265–3266. Bibcode:1998JAChS.120.3265Z. doi:10.1021/ja973478k. Xie, X.; Zubarev, R. A. (2015). "Isotopic resonance hypothesis: experimental verification by Escherichia coli growth measurements". Scientific Reports. 5 9215: 9210. arXiv:1407.4847. Bibcode:2015NatSR...5.9215X. doi:10.1038/srep09215. PMID 25782666. Yang, H.; Lyutvinskiy, Y.; Herukka, S.-K.; Soininen, H.; Rutishauser, D.; Zubarev, R. A. (2014). "Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression". Journal of Alzheimer's Disease. 40 (3): 659–666. doi:10.3233/JAD-132102. PMID 24503613. Xie, X.; Backman, D.; Lebedev, A. T.; Artaev, V. B.; Jiang, L.; Ilag, L. L.; Zubarev, R. A. (2015). "Primordial soup was edible: abiotically produced Miller–Urey mixture supports bacterial growth". Scientific Reports. 5 14338. Bibcode:2015NatSR...514338X. doi:10.1038/srep14338. PMC 4585927. PMID 26412575.

In late 2008, Valve released lifetime retail sales figures as part of a company profile in Game Informer magazine. The two main Half-Life games had sold 15.8 million units at retail (9.3 million for the first, 6.5 million for the second), while the Half-Life expansions had sold 1.9 million (Opposing Force: 1.1 million, Blue Shift: 800,000) and Half-Life 2 expansions 1.4 million units (all for Episode One) by the end of November 2008. Additionally, The Orange Box, which included Half-Life 2 and both of its episodic expansions, sold 3 million units at retail by November 2008. This put franchise sales at around 18.8 million full games (Half-Life: 9.3m, Half-Life 2: 6.5m) and approximately 6.3 million expansions (Opposing Force: 1.1m, Blue Shift: 0.8m, Episode One: 1.4m, Episode 2: 3.0m) at the same month. These figures did not account for digital sales. Half-Life: Counter-Strike sold 4.2 million units standalone by the same time, while its remake, Counter-Strike: Source was bundled with every sold retail copy of Half-Life 2. Forbes reported that, including digital sales, Half-Life 2 had sold over 12 million copies by February 2011.

Sources: en.wikipedia.org

Frequently asked questions

Which receptor mediates the main effect?

MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.

How long does the compound stay in the body?

Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.

Are drug interactions a concern?

Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.

How is the approved product administered?

The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.

Network